RET encodes a receptor tyrosine kinase that helps regulate cell growth and differentiation. When this gene is altered, it can drive medullary thyroid carcinoma in MEN2A and MEN2B. The syndromes share key risks, yet differ in features such as hyperparathyroidism and mucosal neuromas.

Multiple Choice

What is the oncogene associated with MEN2a and MEN2b thyroid cancer?

The oncogene associated with both MEN2a and MEN2b thyroid cancers is RET. This gene encodes a receptor tyrosine kinase that plays a crucial role in cell signaling pathways that regulate cell growth and differentiation. Mutations in the RET gene lead to the development of medullary thyroid carcinoma, which is a hallmark of multiple endocrine neoplasia type 2 syndromes. In MEN2a, the RET mutations can also lead to pheochromocytoma and primary hyperparathyroidism, while in MEN2b, they are associated with a more aggressive form of medullary thyroid carcinoma, pheochromocytomas, and mucosal neuromas. The involvement of RET in these syndromes underscores its significance in the tumorigenesis of these specific cancer types. Other oncogenes listed, such as KRAS, TP53, and APC, are involved in different cancer pathways or syndromes but do not have a direct association with MEN2a or MEN2b thyroid cancer. For instance, KRAS mutations are frequently seen in colorectal cancer and other tumors, while TP53 is a well-known tumor suppressor gene frequently mutated in various cancers. APC is also involved in familial adenomatous polyposis, primarily affecting

RET and the Thyroid Cancers of MEN2

RET is a gene with an outsized role in a small but important group of inherited endocrine conditions. When certain inherited changes switch RET on too strongly, cells in the thyroid can grow into medullary thyroid carcinoma (MTC), a cancer that may occur as part of multiple endocrine neoplasia type 2, or MEN2. The same gene links two distinct forms of the syndrome, MEN2A and MEN2B, though their other features and typical patterns differ.

That connection matters because MEN2 is not simply a thyroid condition. It can affect the adrenal glands and, in MEN2A, the parathyroid glands as well. Understanding RET helps make sense of how these findings fit together—and why identifying an inherited change can matter for more than one family member.

What RET does in a healthy cell

RET is a proto-oncogene: a normal gene that helps regulate cell growth and development but can contribute to cancer if altered in a way that drives excessive activity. It encodes a receptor tyrosine kinase, a protein that sits in the cell membrane and relays signals from outside the cell to its interior. In broad terms, it helps tell certain cells when to grow, mature, or survive.

Normally, RET activity is controlled. It responds to signals involving glial cell line-derived neurotrophic factor family ligands and their co-receptors. A useful analogy is a doorbell: an outside signal presses the button, and the receptor passes a message inside. In MEN2, specific RET variants can act more like a doorbell stuck in the pressed position. The cell keeps receiving growth signals even when it shouldn’t.

This is a gain-of-function effect. It differs from the way many cancer-related genes, such as TP53, are involved in disease. TP53 is a tumor suppressor gene, which normally helps prevent abnormal cells from surviving or dividing. RET, by contrast, can promote cancer when its signaling is overly active. The distinction—too much growth signaling versus loss of a cellular brake—is a useful way to organize a complicated topic.

Why the thyroid is involved

The thyroid contains several cell types. Most thyroid cancers arise from follicular cells, which produce thyroid hormones. MTC begins in the parafollicular cells, also called C cells. These cells make calcitonin, a hormone involved in calcium regulation.

In MEN2, a germline RET variant—one present in the body’s cells and potentially passed from parent to child—can drive abnormal growth of C cells. The earliest change may be C-cell hyperplasia, an increase in the number of these cells. Over time, this can progress to MTC. Because the underlying gene change is inherited, tumors may arise at a younger age or in more than one related person, rather than appearing as an isolated event.

Not every MTC is inherited. Many cases occur sporadically, without a family history or germline RET variant. Some sporadic tumors have changes in RET that developed only within the tumor; others involve different molecular pathways, including RAS. So RET is central to MEN2-associated MTC, but it does not explain every case of medullary thyroid cancer.

MEN2A: a pattern across several glands

MEN2A commonly involves MTC, pheochromocytoma, and primary hyperparathyroidism. A pheochromocytoma is a tumor of the adrenal medulla that can release catecholamines, hormones such as adrenaline. Primary hyperparathyroidism occurs when one or more parathyroid glands produce too much parathyroid hormone, which can disturb calcium levels.

The RET variants linked to MEN2A often affect cysteine residues in the receptor’s extracellular region. These changes can encourage abnormal receptor pairing and persistent signaling. Specific variants are associated with different levels of risk, and that variation can shape clinical decisions.

MEN2A does not mean that every person will develop every feature. Some people have MTC as the only recognized finding; others develop adrenal or parathyroid disease as well. Even within one family, the age of onset and combination of findings can vary. That’s one reason clinicians consider the exact RET variant alongside a person’s health history and family history.

MEN2B: a different clinical picture

MEN2B is less common and often more aggressive. MTC may develop early, and the associated RET variants frequently involve the M918T change in the receptor’s kinase domain. This variant can drive strong signaling and is linked to early-onset disease.

MEN2B can also involve pheochromocytomas. Other clues include mucosal neuromas—small, benign growths around the lips, tongue, or inside the mouth—and a marfanoid body habitus, meaning long limbs and a slender build that can resemble features seen in Marfan syndrome. Some people also have intestinal ganglioneuromatosis, an overgrowth of nerve cells in the digestive tract that may affect bowel function.

Primary hyperparathyroidism is not a typical feature of MEN2B. This contrast can help distinguish the two syndromes, though real clinical patterns do not always fit neatly into a list. The key point is that MEN2A and MEN2B share RET-driven MTC but are not interchangeable labels.

What the genetic link changes

A confirmed germline RET variant can help guide care for the person who carries it and relatives who may share it. Genetic counseling can explain what the result means, how it is inherited, and what choices relatives may have about testing. MEN2 is generally inherited in an autosomal dominant pattern: a person with a pathogenic variant has a one-in-two chance of passing it to each child.

Because MTC can arise early, care teams may discuss thyroid evaluation and preventive thyroid surgery based on the specific variant and the person’s circumstances. The timing is not identical for everyone. It can depend on the RET change, age, calcitonin levels, imaging, and other clinical details. A genetic result is therefore not a complete plan by itself; it is one important piece of a broader picture.

Screening for associated tumors matters, too. In someone with MEN2, clinicians assess for pheochromocytoma and, when relevant, parathyroid disease. Finding a pheochromocytoma before certain procedures is especially important because excess catecholamines can pose serious risks. Care is coordinated across specialties, often including endocrinology, genetics, surgery, and oncology.

How RET fits among other cancer genes

KRAS, TP53, and APC are all important in cancer biology, but they play different roles. KRAS is a signaling gene frequently altered in several tumor types. TP53 helps protect cells from accumulating dangerous changes. APC helps regulate cell growth in the intestine; inherited APC variants can cause familial adenomatous polyposis, a condition associated with numerous colorectal polyps and increased cancer risk.

These genes can appear in broad discussions of cancer, but they do not define MEN2-associated MTC. RET is the key inherited driver in MEN2A and MEN2B. Keeping the genes’ roles distinct prevents a common mix-up: several genes can influence cell growth, but each has its own signaling pathway, associated conditions, and clinical meaning.

One gene, a family-wide story

RET shows how a change in one gene can affect more than one organ and shape health across generations. In MEN2, its overactive signaling connects C-cell growth in the thyroid with other endocrine findings, while the particular variant helps explain why MEN2A and MEN2B look different.

The biology is precise, but the human side is just as important. A genetic finding may bring uncertainty, yet it can also give families a clearer map of what to watch for and who might benefit from evaluation. That’s the value of understanding RET: it turns a molecular detail into information that can guide care, conversations, and decisions across a family.